Antibody-Modified Liposomes Synthesis Service

Comprehensive Services for Antibody-Modified Liposomes Synthesis

At BOC Sciences, our lipid microsphere synthesis services cover the full spectrum of preclinical formulation development. We customize each project based on the physicochemical characteristics of the payload and the intended delivery route, ensuring consistent performance across in vitro and in vivo models.

Schematic structure of antibody-modified liposomes or immunoliposomes. (BOC Sciences Original)

Step-by-Step Process of Antibody-Modified Liposomes Synthesis Service

BOC Sciences follows a rigorously defined and quality-controlled workflow to ensure every batch of antibody-functionalized liposomes meets the highest standards for preclinical research.

1. Project Consultation & Feasibility Assessment

• Review of customer's target, antibody specifications, and intended application
• Evaluation of liposome type, payload, surface modification feasibility, and conjugation route

2. Custom Liposome Preparation & Characterization

• Synthesis of liposomes with customized lipid composition (e.g., PEGylated lipids, cationic lipids, neutral lipids)
• Encapsulation of payload (if applicable)
• Pre-conjugation characterization: size, polydispersity index (PDI), zeta potential

3. Antibody Pre-Processing

• Buffer exchange, purification, and optional antibody fragmentation
• Functional group introduction or reduction (e.g., thiolation, biotinylation)

4. Conjugation Reaction

• Execution of optimized conjugation chemistry (e.g., maleimide-thiol, click chemistry)
• Monitoring of reaction kinetics and antibody-to-lipid ratio

5. Purification of Immunoliposomes

• Removal of unbound antibodies and reagents by SEC, ultrafiltration, or centrifugation
• Yield optimization without compromising liposome integrity

6. Post-Conjugation Characterization

• Confirmation of antibody attachment (e.g., SDS-PAGE, ELISA, flow cytometry)
• Final physicochemical profiling: particle size, PDI, surface charge, stability

7. Documentation & Delivery

• Comprehensive COA and technical report
• Optional stability, storage, or formulation studies
• Secure packaging and global shipment

Benefits of Our Antibody-Modified Liposomes Synthesis Service

BOC Sciences offers unparalleled expertise in self-adjuvanting liposomal vaccine development. Our advantages include:

Applications of Our Antibody-Modified Liposomes Synthesis Service

Antibody-modified liposomes, also known as immunoliposomes, have transformed the paradigm of targeted drug delivery by combining the vesicular encapsulation capability of liposomes with the molecular recognition specificity of monoclonal antibodies. At BOC Sciences, our antibody-modified liposomes synthesis service supports a broad array of advanced biomedical research and preclinical development programs. The following highlights key applications where our engineered immunoliposomes offer strategic and functional value:

Targeted Anticancer Drug Delivery

One of the most advanced applications of antibody-functionalized liposomes lies in tumor-specific drug delivery systems. By conjugating tumor-associated antigen (TAA)-specific antibodies (e.g., anti-HER2, anti-EGFR, anti-CD44) onto liposomal surfaces, our immunoliposomes achieve preferential accumulation in malignant tissues via receptor-mediated endocytosis, significantly improving therapeutic indices while reducing systemic toxicity.

• Example: Anti-HER2 liposomes loaded with doxorubicin or paclitaxel for HER2+ breast and gastric cancers.
• Optimization: We offer fine-tuned antibody orientation and PEGylation density to mitigate immunogenicity while preserving binding affinity in solid tumor models.

Targeted Gene and RNA Therapeutics Delivery

Antibody-modified liposomes have emerged as effective carriers for siRNA, mRNA, and plasmid DNA delivery to specific cell populations. This application is pivotal in gene silencing studies, CRISPR-Cas9 gene editing systems, and RNA vaccine development.

• Example: Anti-CD4 or anti-CD3 liposomes for targeted delivery to T cells in immunological research.
• Technical Highlight: Our formulation platform enables electrostatic or ionizable lipid-assisted encapsulation while preserving nucleic acid integrity and functional activity.

Central Nervous System (CNS) Targeting

The blood-brain barrier (BBB) presents a major obstacle in neurotherapeutics. Antibody-conjugated liposomes targeting transferrin receptors (TfR), insulin receptors, or LRP1 enable transcytosis across the BBB, allowing efficient delivery of neuroprotective agents and biologics to the brain.

• Use Cases: Delivery of small-molecule neuroprotectants or anti-Aβ antibodies for Alzheimer's research.
• Support: We provide CNS-optimized lipid formulations with enhanced stability in cerebrospinal fluid (CSF) environments.

Infectious Disease Models and Vaccine Delivery

Immunoliposomes targeting surface markers of infected cells (e.g., HIV, HBV) or antigen-presenting cells (e.g., dendritic cells, macrophages) serve as innovative platforms for antiviral agents and vaccine antigens. This includes both prophylactic and therapeutic vaccine delivery applications.

• Example: Anti-DEC-205 modified liposomes for antigen delivery to dendritic cells in vaccine development.
• Benefit: Enhanced antigen presentation and immune priming due to co-delivery of adjuvants in liposomal bilayers.

Inflammatory and Autoimmune Disease Targeting

Antibody-functionalized liposomes directed against activated endothelial cells (e.g., anti-ICAM-1, anti-VCAM-1) or immune cell subsets (e.g., anti-CD11b, anti-CCR2) provide cell-specific delivery of immunomodulators in autoimmune or chronic inflammatory conditions.

• Application Areas: Rheumatoid arthritis, multiple sclerosis, atherosclerosis.
• Innovation: Use of liposomes to localize anti-inflammatory agents (e.g., corticosteroids, methotrexate) at the disease site, sparing healthy tissues.

FAQs – Insights about Our Antibody-Modified Liposomes Synthesis Service

Can you help determine the optimal antibody orientation on the liposome surface?

Yes. Our team applies site-directed conjugation strategies (e.g., Fc-specific linking, glycan engineering) to ensure that the antigen-binding domains are exposed outward for maximum targeting efficiency.

What antibody-to-lipid ratio do you recommend for efficient targeting?

While optimal ratios depend on the target cell density and payload, we typically explore a range of antibody densities during pilot studies (e.g., 0.5% to 5% molar ratio) to identify the best-performing formulation under preclinical conditions.

Can liposomes be conjugated with multiple antibodies simultaneously for dual targeting?

Yes. We offer dual or multi-antibody conjugation services for applications such as heterogenous tumor targeting or immune cell redirection. This requires careful surface density control and orientation preservation, both of which are standard in our workflows.

How do you ensure the antibody remains functional after conjugation?

We use mild, non-denaturing conjugation chemistries and validate antibody integrity via ELISA, SPR, or flow cytometry. Post-conjugation activity is confirmed through antigen-binding assays using relevant cell lines or recombinant targets.

What size range and surface charge can be achieved for antibody-modified liposomes?

We produce liposomes typically ranging from 80 to 200 nm in diameter with tunable surface charge (cationic, neutral, anionic) to suit specific biodistribution or cellular uptake needs.

Can you scale up the antibody-modified liposome formulation for larger preclinical studies?

Absolutely. Our platform supports milligram to multi-gram scale-up using microfluidics, high-pressure homogenization, or extrusion-based methods, with full scalability and batch consistency.

For further collaboration or to initiate a custom synthesis project, please contact our liposomal technology team at BOC Sciences, where scientific precision meets formulation innovation.